Daratumumab (Darzalex®)

Assessment Status NCPE Assessment Process Complete
Drug Daratumumab
Brand Darzalex®
Indication For the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Assessment Process
Rapid review commissioned 31/05/2016
Rapid review completed 14/06/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 27/10/2016
NCPE assessment completed 03/03/2017
NCPE assessment outcome The cost effectiveness of daratumumab  (Darzalex®) monotherapy  has not been demonstrated. Therefore it is not recommended for reimbursement.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations; April 2018.